Hepatitis B virus (HBV) serum biomarkers for screening and monitoring infections at Rio de Janeiro, Brazil
1 Department of Sciences Medicine, All Lab World Medical Clinic, Presidente Vargas, 529 - Centro, Rio de Janeiro, Brazil.
2 Department of Sciences Veterinary, Clinic Dr. André Luiz, Ramos da Fonseca, 74 - Lins de Vasconcelos, Brazil.
3 Department of Health and Agricultural Sciences, Santa Úrsula University, Fernando Ferrari, 75 – Botafogo, Rio de Janeiro, Brazil.
Research Article
World Journal of Advanced Research and Reviews, 2023, 20(01), 439–446
Article DOI: 10.30574/wjarr.2023.20.1.1944
Publication history:
Received on 14 August 2023; revised on 29 September 2023; accepted on 02 October 2023
Abstract:
HBV is a short-term disease and is one of the major causative agents of chronic liver illness. For others, it can become a long-term, chronic infection like liver disease or liver cancer. This paper was aimed to investigate the blood-based serum biomarkers for screening and monitoring of Brazilian patients collected in the All Lab at Rio de Janeiro city. This research were carried out using the chemiluminescence method. The presence (reactive) or absence of anti-HBV antibodies (non-reactive) was also investigated by the electrochemiluminescence. The serological diagnosis of hepatitis B involves the evaluation of antigens and antibodies. Our findings had been showed which it is possible to determine the different phases of the infection (reactive – positive or non-reactive – negative) and some samples can be resulted indeterminates or inconclusive by the choice method and the immune system or susceptible of the patients. The sum of numbers, average, standard deviation and coefficient of variation were calculated among the 2222 samples collected from 1660 patients and 477 samples from 411 patients from the year 2022 and 2023, respectively. So, irrespective of HBV genotype or infection phase, this paper provides a classic way fast-track to advance the HBV serum biomarkers detected in blood samples. Novel challenges of serum HBV biomarkers should be more discussed to mitigated weaknesses points and eliminate cross-reaction in clinical assays.
Keywords:
HBV; Biomarkers; Liver disease; Serological assays; Screening and monitoring infections.
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0